BRCAness as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer

Hitomi Mori, Makoto Kubo, Reiki Nishimura, Tomofumi Osako, Nobuyuki Arima, Yasuhiro Okumura, Masayuki Okido, Mai Yamada, Masaya Kai, Junji Kishimoto, Tetsuyuki Miyazaki, Yoshinao Oda, Takao Otsuka, Masafumi Nakamura

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and BRCA1-mutated tumors, in a large cohort of TNBC cases. Methods The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the isolation of DNA from tumor tissue. Classification of BRCAness was performed using multiple ligation-dependent probe amplification (MLPA). The tumor subtypes were determined immunohistochemically using resected specimens. Results Of the 262 TNBCs, the results of the MLPA assays showed that 174 (66.4%) tumors had BRCAness. Patients with BRCAness tumors were younger than patients with non-BRCAness tumors (P = 0.003). There was no significant difference between the two groups regarding their pathological stages. The BRCAness group had a significantly shorter recurrence-free survival (RFS) compared with the non-BRCAness group (P = 0.04) and had a shorter overall survival (OS) although this did not reach statistical significance. Adjuvant treatments with anthracycline-based regimens provided significantly greater benefits to the BRCAness group (P = 0.003 for RFS, and P = 0.03 for OS). Multivariate Cox proportional hazard model analysis showed that BRCAness was an independent negative prognostic factor, and the anthracycline-based adjuvant chemotherapy was an independent positive prognostic factor for both RFS and OS in TNBC. Conclusions The 66.4% patients of TNBCs showed BRCAness. BRCAness is essential as a biomarker in the subclassification of TNBCs and might be of use for predicting their prognosis. Furthermore, this biomarker might be a predictive factor for the effectiveness of anthracyclinebased adjuvant chemotherapy for patients with TNBCs.

Original languageEnglish
Article numbere0167016
JournalPloS one
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

anthracyclines
Triple Negative Breast Neoplasms
Chemotherapy
Anthracyclines
Biomarkers
Adjuvant Chemotherapy
breast neoplasms
prognosis
drug therapy
adjuvants
Tumors
biomarkers
neoplasms
Survival
Neoplasms
Recurrence
Ligation
Amplification
Proportional Hazards Models
Assays

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

BRCAness as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer. / Mori, Hitomi; Kubo, Makoto; Nishimura, Reiki; Osako, Tomofumi; Arima, Nobuyuki; Okumura, Yasuhiro; Okido, Masayuki; Yamada, Mai; Kai, Masaya; Kishimoto, Junji; Miyazaki, Tetsuyuki; Oda, Yoshinao; Otsuka, Takao; Nakamura, Masafumi.

In: PloS one, Vol. 11, No. 12, e0167016, 01.12.2016.

Research output: Contribution to journalArticle

Mori, Hitomi ; Kubo, Makoto ; Nishimura, Reiki ; Osako, Tomofumi ; Arima, Nobuyuki ; Okumura, Yasuhiro ; Okido, Masayuki ; Yamada, Mai ; Kai, Masaya ; Kishimoto, Junji ; Miyazaki, Tetsuyuki ; Oda, Yoshinao ; Otsuka, Takao ; Nakamura, Masafumi. / BRCAness as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer. In: PloS one. 2016 ; Vol. 11, No. 12.
@article{d11e73373a3248ac9f77b800e5b0b76e,
title = "BRCAness as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer",
abstract = "Background Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and BRCA1-mutated tumors, in a large cohort of TNBC cases. Methods The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the isolation of DNA from tumor tissue. Classification of BRCAness was performed using multiple ligation-dependent probe amplification (MLPA). The tumor subtypes were determined immunohistochemically using resected specimens. Results Of the 262 TNBCs, the results of the MLPA assays showed that 174 (66.4{\%}) tumors had BRCAness. Patients with BRCAness tumors were younger than patients with non-BRCAness tumors (P = 0.003). There was no significant difference between the two groups regarding their pathological stages. The BRCAness group had a significantly shorter recurrence-free survival (RFS) compared with the non-BRCAness group (P = 0.04) and had a shorter overall survival (OS) although this did not reach statistical significance. Adjuvant treatments with anthracycline-based regimens provided significantly greater benefits to the BRCAness group (P = 0.003 for RFS, and P = 0.03 for OS). Multivariate Cox proportional hazard model analysis showed that BRCAness was an independent negative prognostic factor, and the anthracycline-based adjuvant chemotherapy was an independent positive prognostic factor for both RFS and OS in TNBC. Conclusions The 66.4{\%} patients of TNBCs showed BRCAness. BRCAness is essential as a biomarker in the subclassification of TNBCs and might be of use for predicting their prognosis. Furthermore, this biomarker might be a predictive factor for the effectiveness of anthracyclinebased adjuvant chemotherapy for patients with TNBCs.",
author = "Hitomi Mori and Makoto Kubo and Reiki Nishimura and Tomofumi Osako and Nobuyuki Arima and Yasuhiro Okumura and Masayuki Okido and Mai Yamada and Masaya Kai and Junji Kishimoto and Tetsuyuki Miyazaki and Yoshinao Oda and Takao Otsuka and Masafumi Nakamura",
year = "2016",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0167016",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - BRCAness as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer

AU - Mori, Hitomi

AU - Kubo, Makoto

AU - Nishimura, Reiki

AU - Osako, Tomofumi

AU - Arima, Nobuyuki

AU - Okumura, Yasuhiro

AU - Okido, Masayuki

AU - Yamada, Mai

AU - Kai, Masaya

AU - Kishimoto, Junji

AU - Miyazaki, Tetsuyuki

AU - Oda, Yoshinao

AU - Otsuka, Takao

AU - Nakamura, Masafumi

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and BRCA1-mutated tumors, in a large cohort of TNBC cases. Methods The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the isolation of DNA from tumor tissue. Classification of BRCAness was performed using multiple ligation-dependent probe amplification (MLPA). The tumor subtypes were determined immunohistochemically using resected specimens. Results Of the 262 TNBCs, the results of the MLPA assays showed that 174 (66.4%) tumors had BRCAness. Patients with BRCAness tumors were younger than patients with non-BRCAness tumors (P = 0.003). There was no significant difference between the two groups regarding their pathological stages. The BRCAness group had a significantly shorter recurrence-free survival (RFS) compared with the non-BRCAness group (P = 0.04) and had a shorter overall survival (OS) although this did not reach statistical significance. Adjuvant treatments with anthracycline-based regimens provided significantly greater benefits to the BRCAness group (P = 0.003 for RFS, and P = 0.03 for OS). Multivariate Cox proportional hazard model analysis showed that BRCAness was an independent negative prognostic factor, and the anthracycline-based adjuvant chemotherapy was an independent positive prognostic factor for both RFS and OS in TNBC. Conclusions The 66.4% patients of TNBCs showed BRCAness. BRCAness is essential as a biomarker in the subclassification of TNBCs and might be of use for predicting their prognosis. Furthermore, this biomarker might be a predictive factor for the effectiveness of anthracyclinebased adjuvant chemotherapy for patients with TNBCs.

AB - Background Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and BRCA1-mutated tumors, in a large cohort of TNBC cases. Methods The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the isolation of DNA from tumor tissue. Classification of BRCAness was performed using multiple ligation-dependent probe amplification (MLPA). The tumor subtypes were determined immunohistochemically using resected specimens. Results Of the 262 TNBCs, the results of the MLPA assays showed that 174 (66.4%) tumors had BRCAness. Patients with BRCAness tumors were younger than patients with non-BRCAness tumors (P = 0.003). There was no significant difference between the two groups regarding their pathological stages. The BRCAness group had a significantly shorter recurrence-free survival (RFS) compared with the non-BRCAness group (P = 0.04) and had a shorter overall survival (OS) although this did not reach statistical significance. Adjuvant treatments with anthracycline-based regimens provided significantly greater benefits to the BRCAness group (P = 0.003 for RFS, and P = 0.03 for OS). Multivariate Cox proportional hazard model analysis showed that BRCAness was an independent negative prognostic factor, and the anthracycline-based adjuvant chemotherapy was an independent positive prognostic factor for both RFS and OS in TNBC. Conclusions The 66.4% patients of TNBCs showed BRCAness. BRCAness is essential as a biomarker in the subclassification of TNBCs and might be of use for predicting their prognosis. Furthermore, this biomarker might be a predictive factor for the effectiveness of anthracyclinebased adjuvant chemotherapy for patients with TNBCs.

UR - http://www.scopus.com/inward/record.url?scp=85006304514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006304514&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0167016

DO - 10.1371/journal.pone.0167016

M3 - Article

C2 - 27977696

AN - SCOPUS:85006304514

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0167016

ER -